Results 171 to 180 of about 34,772,816 (303)

Über einige Reaktionen des Selentrioxids III

CHIMIA, 1967
P. Martin, A. Scholer, E. Class
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

HLA class I expression and tumor immune infiltration together shape colon cancer immune contexture. [PDF]

Neoplasia
Zhu H, van Nieuwkerk R, van der Kroft S, van Vlierberghe RLP, IJsselsteijn ME, Zuo W, Hviid TVF, Tollenaar RAEM, Vahrmeijer AL, Bedognetti D, Hendrickx WRL, Roelands J, Kuppen PJK.   +12 more
europepmc   +1 more source

Zur heterogenen Katalyse der Bildung von Fluorophosphaten

CHIMIA, 1968
W. Fringeli, E. Class, H. Erlenmeyer
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Diverse ancestral myosin motors generate and segregate distinct types of nanocluster-rich domains at the plasma membrane. [PDF]

Sci Adv
Sil P, van Zanten TS, Jahnavi S, Bansal A, Razmazma H, Saha S, Mahajan B, Kumar M, Stansfeld PJ, Singh PP, Rao M, Mayor S.   +11 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Association between latent classes of tobacco, e-cigarette, alcohol, and illicit drug use patterns and depression among Thai adolescents. [PDF]

Addict Behav Rep
Sagayanathan R, Wichaidit W, Stafström M.   +2 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Selected clinical approaches for the treatment of classic Class II, division 1 malocclusion. [PDF]

Dental Press J Orthod
Tanaka OM, Gasparello GG, Pithon MM, Antelo OM, Martins RP.   +4 more
europepmc   +1 more source